Zura Bio Ltd. is a clinical-stage biotechnology company, which engages in the development of novel medicines for immune disorders. The company is headquartered in La Jolla, California and currently employs 30 full-time employees. The company went IPO on 2021-07-16. The company is developing three assets which have completed Phase I/Ib studies. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
Follow-Up Questions
Zura Bio Ltd의 CEO는 누구입니까?
Mr. Robert Lisicki은 2024부터 회사에 합류한 Zura Bio Ltd의 Chief Executive Officer입니다.
ZURA 주식의 가격 성능은 어떻습니까?
ZURA의 현재 가격은 $3.25이며, 전 거래일에 increased 1.52% 하였습니다.
Zura Bio Ltd의 주요 사업 주제나 업종은 무엇입니까?
Zura Bio Ltd은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Zura Bio Ltd의 시가총액은 얼마입니까?
Zura Bio Ltd의 현재 시가총액은 $211.8M입니다
Zura Bio Ltd는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 8명의 분석가가 Zura Bio Ltd에 대한 분석 평가를 실시했으며, 이는 5명의 강력한 매수, 6명의 매수, 2명의 보유, 0명의 매도, 그리고 5명의 강력한 매도를 포함합니다
